Glenmark Pharmaceuticals — Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is a Public Non-govt company company incorporated in 1977 and based in Maharashtra, India. Glenmark Pharmaceuticals Limited operates in Anti-freeze preparations, manufacturing (NIC 24299) with authorized capital of ₹277.00 Cr and paid-up capital of ₹28.22 Cr. For 2025-26, the company reported revenue of ₹8440.10 Cr and a net loss of ₹200.80 Cr. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 67/100 (grade C), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
Glenmark Pharmaceuticals - R&D company focused on manufacturing generic drugs for multiple therapeutic areas. Public Company. Raised funding over 1 round from 3 investors.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +33d | filed |
| MGT-7 | FY2024-25 | 23 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 27 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | +8d | filed |
| MGT-7 | FY2022-23 | 25 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Glenmark Pharmaceuticals Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 720168476 | State Bank of India(Bank) | ₹9.28 Cr | 12 Mar 2021 | Satisfied |
| 100844856 | State Bank of India(Bank) | ₹1.42 Cr | 19 Sep 2022 | Open |
| 476536992 | Axis Bank Ltd(Bank) | ₹1.90 Cr | 12 Mar 2020 | Open |
| 705210913 | HDFC Bank Ltd(Bank) | ₹13.75 Cr | 04 Jul 2022 | Satisfied |
Charge IDs, lenders & amounts for Glenmark Pharmaceuticals Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2025-26 | — | ||||
| 2020-21 | — |
Detailed Financials
2 FYs| Line item | 2025-26 | 2020-21 |
|---|---|---|
| Income statement | ||
| Revenue from operations | ||
| Other income | ||
| Total income | ||
| Total expenses | ||
| Profit before tax | ||
| Profit / (Loss) after tax | ||
| Balance sheet | ||
| Equity / Net worth | ||
| Borrowings | ||
| Current liabilities | ||
| Total liabilities | ||
| Current assets | ||
| Cash & equivalents | ||
| Total assets | ||
| Employees | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2025-26 | +98.0% | — | — | |
| Profit after Tax2025-26 | -544.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2020-21 | +21.80% | — | +11.14% | +8.00% | 0.39 | |||
| 2025-26 | -2.38% | +11.52% | — | — | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 3 | 59,41,510 | 77.17% |
| Institutional Investors | 2 | 7,16,853 | 9.31% |
| Public & Others | 22 | 10,40,697 | 13.52% |
Promoter, institutional & public holding for Glenmark Pharmaceuticals Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
500 peersEvents & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.